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The aim of the present study was to determine the outcome of patients undergoing pancreatic resection with (VR+) or without
(VR−) mesenteric-portal vein resection for pancreatic carcinoma. Between January 1998 and December 2012, 241 patients with
pancreatic cancer underwent pancreatic resection: in 64 patients, surgery included venous resection for macroscopic invasion of
mesenteric-portal vein axis. Morbidity and mortality did not differ between the two groups (VR+: 29% and 3%; VR−: 30% and
4.0%, resp.). Radical resection was achieved in 55/64 (78%) in the VR+ group and in 126/177 (71%) in the VR− group. Vascular
invasion was histologically proven in 44 (69%) of the VR+ group. Survival curves were not statistically different between the two
groups. Mean andmedian survival time were 26 and 15 months, respectively, in VR− versus 20 and 14 months, respectively, in VR+
group (𝑝 = 0.52). In the VR+ group, only histologically proven vascular invasion significantly impacted survival (𝑝 = 0.02), while,
in the VR− group, R0 resection (𝑝 = 0.001) and tumor’s grading (𝑝 = 0.01) significantly influenced long-term survival. Vascular
resection during pancreatectomy can be performed safely, with acceptable morbidity and mortality. Long-term survival was the
same, with or without venous resection. Survival was worse for patients with histologically confirmed vascular infiltration.
1. Introduction
Involvement of peripancreatic large blood vessels is detected
in about half of pancreas cancers [1] and has been generally
considered a contraindication to surgery, for many years.
In fact, vascular resection was widely considered a difficult
surgical procedurewith high incidence of complications [2, 3]
and without significant effectiveness in survival, compared to
palliative operations [4, 5]. Nevertheless, surgical resection
is still considered the only curative opportunity for patients
affected by pancreatic cancer and, nowadays, it is considered
an effective palliative procedure due to improvement of
morbidity and mortality rates after surgery [6–9]. Moreover,
in the last two decades, an increasing number of venous
resections were reported in centers with high volume of
pancreatic surgery, while arterial resection still remains an
isolated exception [10].
Aim of this study is to present our single center experi-
ence of venous resections during pancreatectomy for pancre-
atic cancer.
2. Patients and Methods
Datawere obtained froma retrospective analysis of a prospec-
tively collected database of 241 patients who underwent
pancreatectomy for pancreatic cancer from January 1998
to December 2012 at our institution. They were divided
in two groups: patients who underwent associated venous
(portal-mesenteric) resection (VR+) and those who under-
went standard resection (VR−). The two groups were com-
pared in terms of demographic features, surgical proce-
dures, tumor pathologic findings, perioperative outcome,
and survival. All surgical procedures were performed by
the same surgical team. All patients underwent standardized
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preoperative assessment: routine blood tests and tumor
markers CEA and CA 19-9 determination, abdominal ultra-
sound (US), computed assisted tomography (CT) scan, and,
when needed, magnetic resonance imaging or positron emis-
sion tomography (PET). CT with angiographic reconstruc-
tion was the preferred imaging for tumor’s staging. Limited
involvement of superior mesenteric-portal axis (less than
2 cm), in absence of extrapancreatic disease and involvement
of superior mesenteric artery and/or celiac trunk, was not
considered as contraindication to surgery. No patient under-
went neoadjuvant therapy.
Surgical technique included standardized lymph node di-
ssection and para-aortic nodes sampling, pylorus-preserving
pancreaticoduodenectomy (PD) for tumors of the head of
the pancreas, and distal pancreatectomywith splenectomy for
tumors of the body/tail. Total pancreatectomywas performed
in selected patients, when resection margin of the pancreas
was involved by the tumor or when pancreatic anastomosis
was judged at high risk of leakage. In VR+ patients, surgical
procedure was similar to standard resection in preparation
and exposure of pancreas, with a wide Kocher maneuver.
Complete evaluation of vascular invasion was determined
after transection of the isthmus; in the last years, we per-
formed translateral approach with dissection of uncinate
process first and subsequent en bloc excision of pancreas
head and infiltrated vein [11]. Vascular resection technique
included tangential resection with linear nonstenosing suture
when a focal invasion of superior mesenteric vein or portal
vein occurred or excision of infiltrated venous tract and
end-to-end anastomosis. In selected cases of longer involve-
ment of vein, a vascular graft with internal jugular vein
was performed. Curative resection was defined as tumor’s
resection with pathologically confirmed negative margins.
R1 resection was defined as the presence of tumor ≤ 1mm
from the margin, according to Leeds criteria [12]. Periop-
erative morbidity and mortality were investigated in both
groups: operative mortality was defined as death within 30
days from operation or during hospitalization. Pancreatic
fistula was defined as the drainage of fluid with an elevated
level of amylase and graded according to the International
Study Group of Pancreatic Fistula recommendations [13]. All
patients underwent regular follow-up that included physical
examination, abdominal CT or US, and tumor markers
determination every 3 months, for the first 2 years, and every
6 months, thereafter.
Survival curves were constructed with the Kaplan-Meier
method and compared by the univariate log-rank test: signif-
icance was considered as 𝑝 < 0.05. Tumor’s stage, grading,
lymph node status, radicality of resection, venous resection,
true venous infiltration, and depth of venous involvement
were considered as prognostic factors. Independent prognos-
tic variables were evaluated with a Cox regression hazard
model. Statistical analysis was performed using the SPSS
statistical software package (version 18.0; SPSS Inc., Chicago,
IL, USA).
Table 1: Clinicopathological features of patients subjected to pan-
creatic resection with (VR+) and without (VR−) vascular resection.
VR+ VR−
(𝑛 = 64) (𝑛 = 177)
Age
Median 60.7 63.7
Range (37–82) (37–84)
Gender
M 23 95
F 30 82
pT1 0 3
T2 3 21
T3 22 149
T4 28 4
Lymph node
Yes 39 117
No 14 60
Grading
G1 14 29
G2 28 95
G3 11 53
Radicality
R0 55 125
R1 9 46
R2 0 6
Type of resection
PD 50 121
TP 10 6
DP 4 50
PD: pancreatoduodenectomy; TP: total pancreatectomy; DP: distal pancrea-
tectomy.
3. Results
Clinicopathologic findings of patients included in the study
are detailed in Table 1. During the study period, resection
rate increased from 18% to 27% in the last 8 years together
with the increasing number of vascular resection. A total of
64 patients (26%) underwent venous resection (27 males and
37 females with mean age of 62.5 yrs; range 37–82). We per-
formed 50 pancreatoduodenectomy (PD) procedures, 10 total
pancreatectomy (TP) procedures, and 4 distal pancreatec-
tomy procedures with splenectomy (DP) (Table 1). Tangential
resection with linear suture was performed in 13 patients and
venous resection with end-to-end anastomosis in 50 patients;
a prosthetic graft was used in 1 patient. According to the
International Study Group of Pancreatic Surgery (ISGPS)
classification, [14], 13 patients underwent type 1, 50 patients
type 3, and 1 patient type 4 venous resection. All patients
exhibited ductal adenocarcinoma at pathologic examination.
Histological examination confirmed vascular invasion in 69%
of cases; 55 patients (86%) had radical resection (R0), and
9 subjects (14%) had microscopic neoplastic residue (R1).
Tumor involved superficial venous wall (up to tunica adven-
titia) in 8 cases, the tunica media in 24 cases, and the tunica
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Table 2: Postoperative outcome of patients after pancreatic resec-
tion with (VR+) and without (VR−) vascular resection.
VR+ VR−
(𝑛 = 64) (𝑛 = 177)
𝑛 (%) 𝑛 (%)
Complications
Pancreatic fistula 7 (11) 23 (13)
Biliary fistula 3 (5) 5 (3)
Fluid collections 4 (6) 9 (5)
Peritoneal bleeding 3 (5) 9 (5)
Digestive bleeding 1 (2) 1 (0.5)
Ileal perforation 1 (2) 5 (3)
Pleural effusion 1 (2) 2 (1)
Others 1 (2) 6 (3)
Reoperation 4 (6) 9 (5)
Morbidity 19 (29%) 53 (30%)
Mortality 2 (3%) 7 (4%)
PD: pancreatoduodenectomy; TP: total pancreatectomy; DP: distal pancrea-
tectomy.
Table 3: Univariate analysis of factors influencing overall survival.
Variables Survival (mo)
Mean Median Significance
Grading
Well-moderate 26.7 17 p = 0.009
Poor 19.8 14
Node status
No 24.7 16 p = 0.977
Yes 23.6 15
Radicality
No 26.6 17 p = 0.001
Yes 19.5 10
Vein resection
No 25.8 15 p = 0.301
Yes 19.9 14
intima in 12 cases. Postoperative outcome is reported in
Table 2. Surgical complications occurred in 21 patients (33%):
7 pancreatic fistulas, 4 abdominal effusions, 3 peritoneal
bleeding cases, 3 biliary fistulas, 1 bowel perforation, 1 bleed-
ing of digestive tract, and 1 pleural effusion. Three patients
underwent reoperation. Postoperative death occurred in 1
(3%) patient. Morbidity rate, types of complication, and
reoperation’s rate were not statistically different in the two
groups of patients: mortality rate in VR− group was 3%
versus 4% in the VR− group (Table 2). Two patients experi-
enced portal vein thrombosis 11 and 13 months after oper-
ation, respectively. Both patients had endoscopic evidence
of gastric varices without episodes of digestive bleeding.
After operation, all patients underwent gemcitabine-based
adjuvant therapy, associated with radiotherapy in cases of R1
resection.
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Figure 1: Overall survival in patients who underwent pancreatic
resection with or without vascular resection.
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Figure 2: Overall survival in patients who underwent pancreatic
resection with vascular resection and histological confirmation of
vascular invasion.
Mean and median overall survival time were 24 and 15
months, respectively. Mean survival time was 26 months for
patients without vascular resection versus 20months for VR+
group, while median survival time was 15 and 14 months,
respectively (𝑝 = 0.31) (Table 3). Mean and median survival
time forVR+groupwithout orwith histological confirmation
of venous involvement were 26 and 22 months versus 17
and 12 months, respectively (𝑝 = 0.02). Median survival in
R0 patients was 17 months versus 10 months in R1 group.
Overall survival was 42% at 1 yr, 10% at 2 yrs, and 2% at 3, 4,
and 5 yrs (Figure 1). In patients without evidence of vascular
invasion, overall survival was 69% at 1 yr, 31% at 2 yrs, 6%
at 3 yrs, and 6% at 5 yrs versus 30% at 1 yr and 0% at 2 yrs
in subjects with confirmed vascular infiltration (Figure 2).
There was a trend of worse prognosis for patients with
deeper portal vein invasion without statistical significance
(𝑝 = 0.08).
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4. Discussion
In our study, we analyzed the outcome after pancreatectomy
with orwithout portal vein resection in a group of 241 patients
with pancreatic cancer. Patients with vascular resection had
similar outcomes compared to patients who underwent stan-
dard resection, with no differences in morbidity, mortality,
and long-term survival. Patients had also similar lengths
of stay. These results compare favorably with that of other
surgical series [15, 16].
The rate of vascular resection during pancreatic operation
is strongly influenced by single centers strategies; in some
series, associated en bloc vascular resection occurs in few
cases [4], and it is depending on careful preoperative selection
of patients or intraoperative findings. Other studies present
high rates of vascular resections probably due to different
behavior related to different persuasions [11].Our department
policy towards resection criteria was to perform venous
resection in all cases of small vein involvement (≤2 cm
in length), in absence of venous occlusion or thrombosis,
in order to obtain an easier end-to-end anastomosis. This
approach did not substantially change during the study
period, although more operations were performed in the last
6 years. Moreover, we observed a trend of better survival in
the last period even though the rate of recurrence after resec-
tion was not significantly modified. It is reasonable to believe
that this fact could be explained by the introduction of more
effective chemotherapeutic regimens (i.e., FOLFIRINOX) for
the treatment of relapsing tumors.
Vascular resection and reconstruction could represent a
theoretical additional risk in pancreatic-surgical procedures
[3]. Nevertheless, morbidity and mortality rates, reported
by many centers, are similar to those related to standard
surgical technique [15, 16]. In our experience, postoperative
complications and mortality rates are comparable with the
most recent reports of other institutions, confirming that
vascular resection does not increase operative risk. In 2012,
Zhou et al. [17] performed a meta-analysis collecting 19 non-
randomized studies, for a total of 2,247 patients.There was no
difference in perioperative morbidity and mortality between
patients with VR and those without VR. More recently, a
meta-analysis of Yu et al. [18] evaluating 22 retrospective
studies including 2890 patients confirmed that there was
no difference in perioperative morbidity and mortality rates
between the two groups of patients, with VR or without
VR. However, this study showed differences in median
tumor size, R0 resection rate, lymph node metastases, and
pancreatic fistula. Although randomized prospective studies
are lacking, there are convincing evidences in the literature
that pancreatectomy associated with vein resection is safe
and feasible and does not increase postoperative morbidity.
Thrombosis of the anastomosed vein may occur late after
operation, as in our series and in another experience [19] but
the risk of digestive bleeding remains only theoretical.
The potential oncological benefit, instead, is still unclear.
In our experience, long-term survival was not statistically
different between patients who underwent venous resection
and those who did not.
Many series of pancreatectomies associated with venous
resection show no difference in terms of survival compared
to standard resections [20], while other centers report poorer
outcome [21]. These differences could be explained by the
possibility to obtain a R0 resection; this parameter is known
to affect prognosis and is reported with a wide range in
other studies (32–87%) [4, 5, 20–22]. In our experience, R0
resections rate was 86% with a median survival of 17 months
versus 10 months for R1 patients. Furthermore, only patients
with R0 resection were alive for 2 years, even in absence of
statistical significance. Recently, in a prospectivemulticentric
study, Delpero et al. [23] reported an increasing frequency of
positive resection margins in patients who required portal-
mesenteric vein resection: this findingwas previously showed
by other authors [24] and associated with tumor’s size and
biology, rather than with vascular resection.
Regarding histological confirmation of vascular infiltra-
tion, this parameterwas not confirmed at histological analysis
in 31% of our cases, with a median survival of 16.5 months
versus 9.5 months in patients with histological report of
vascular invasion (𝑝 = 0.02).These data suggest a satisfactory
oncological benefit of vascular resection especially in selected
patients with inflammatory vascular adherence [25]. How-
ever, better survival after pancreatectomy with venous resec-
tion compared to palliative surgical bypass has been reported
[16]. Moreover, it is difficult to distinguish true neoplastic
involvement from inflammatory adhesion both pre- and
intraoperatively, so whenever possible, pancreatectomy with
vascular resection is advisable to reach a radical resection
together with the best tumor’s staging. The depth of tumor
invasion has been shown to be a negative prognostic factor.
Fukuda et al. [26] showed that the deeper invasion (tunica
media or intima) was an independent prognostic marker
for poorer survival, with median survival similar to that of
nonresected patients. In our experience, there was a trend
to worse prognosis when deeper portal vein wall invasion
occurred, but without statistical significance. Further studies
are necessary to evaluate the depth of vein involvement as a
possible contraindication to resection.
5. Conclusion
In conclusion, vascular resection seems to offer an onco-
logical benefit when it increases tumor’s resectability and
R0 resection rates [27], in absence of other parameters
affecting prognosis. Vascular resection presents acceptable
perioperativemorbidity andmortality rates, when performed
in specialized centers; nevertheless, long-term survival rates
are still conflicting and careful evaluation and selection of
patients are recommended.
Conflict of Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper.
References
[1] K. D. Lillemoe, P. K. Sauter, H. A. Pitt, C. J. Yeo, and J. L.
Cameron, “Current status of surgical palliation of periampul-
lary carcinoma,” Surgery Gynecology and Obstetrics, vol. 176, no.
1, pp. 1–10, 1993.
Gastroenterology Research and Practice 5
[2] T. Nagakawa, I. Konishi, K. Ueno et al., “Surgical treatment
of pancreatic cancer. The Japanese experience,” International
Journal of Pancreatology, vol. 9, no. 1, pp. 135–143, 1991.
[3] S. Tashiro, R. Uchino, T. Hiraoka et al., “Surgical indication and
significance of portal vein resection in biliary and pancreatic
cancer,” Surgery, vol. 109, no. 4, pp. 481–487, 1991.
[4] B. Launois, J. Franci, E. Bardaxoglou et al., “Total pancreatec-
tomy for ductal adenocarcinoma of the pancreas with special
reference to resection of the portal vein and multicentric
cancer,”World Journal of Surgery, vol. 17, no. 1, pp. 122–127, 1993.
[5] J. D. Roder, H. J. Stein, and J. R. Siewert, “Carcinoma of the
periampullary region: who benefits fromportal vein resection?”
TheAmerican Journal of Surgery, vol. 171, no. 1, pp. 170–175, 1996.
[6] M. Hartel, M. Niedergethmann, M. Farag-Soliman et al.,
“Benefit of venous resection for ductal adenocarcinoma of the
pancreatic head,” European Journal of Surgery, vol. 168, no. 12,
pp. 707–712, 2002.
[7] J. P. Neoptolemos, R. C. G. Russell, S. Bramhall, and B.
Theis, “Low mortality following resection for pancreatic and
periampullary tumours in 1026 patients: UK survey of specialist
pancreatic units,” British Journal of Surgery, vol. 84, no. 10, pp.
1370–1376, 1997.
[8] D. J. Gouma, E. J. M. N. van Dijkum, R. C. I. van Geenen, T. M.
van Gulik, and H. Obertop, “Are there indications for palliative
resection in pancreatic cancer?” World Journal of Surgery, vol.
23, no. 9, pp. 954–959, 1999.
[9] K. Ouchi, T. Sugawara, H. Ono et al., “Palliative operation
for cancer of the head of the pancreas: significance of pan-
creaticoduodenectomy and intraoperative radiation therapy for
survival and quality of life,”World Journal of Surgery, vol. 22, no.
4, pp. 413–417, 1998.
[10] S. Matsuno, S. Egawa, S. Fukuyama et al., “Pancreatic cancer
registry in Japan: 20 years of experience,” Pancreas, vol. 28, no.
3, pp. 219–230, 2004.
[11] O. Ishikawa, “Surgical technique, curability and postoperative
quality of life in an extended pancreatectomy for adenocarci-
noma of the pancreas,” Hepato-Gastroenterology, vol. 43, no. 8,
pp. 320–325, 1996.
[12] K. V. Menon, D. Gomez, A. M. Smith, A. Anthoney, and C. S.
Verbeke, “Impact of margin status on survival following pan-
creatoduodenectomy for cancer: the Leeds Pathology Protocol
(LEEPP),” HPB, vol. 11, no. 1, pp. 18–24, 2009.
[13] C. Bassi, C. Dervenis, G. Butturini et al., “Postoperative pan-
creatic fistula: an international study group (ISGPF) definition,”
Surgery, vol. 138, no. 1, pp. 8–13, 2005.
[14] M. Bockhorn, F. G. Uzunoglu, M. Adham et al., “Borderline
resectable pancreatic cancer: a consensus statement by the
International Study Group of Pancreatic Surgery (ISGPS),”
Surgery, vol. 155, no. 6, pp. 977–988, 2014.
[15] Y. Gong, L. Zhang, T. He et al., “Pancreaticoduodenectomy
combined with vascular resection and reconstruction for
patients with locally advanced pancreatic cancer: a multicenter,
retrospective analysis,” PLoS ONE, vol. 8, no. 8, Article ID
e70340, 2013.
[16] R. Ravikumar, C. Sabin, M. Abu Hilal et al., “Portal vein
resection in borderline resectable pancreatic cancer: a United
Kingdom multicenter study,” Journal of the American College of
Surgeons, vol. 218, no. 3, pp. 401–411, 2014.
[17] Y. Zhou, Z. Zhang, Y. Liu, B. Li, and D. Xu, “Pancreatectomy
combined with superior mesenteric vein-portal vein resec-
tion for pancreatic cancer: a meta-analysis,” World Journal of
Surgery, vol. 36, no. 4, pp. 884–891, 2012.
[18] X. Z. Yu, J. Li, D. L. Fu et al., “Benefit from synchronous
portal-superior mesenteric vein resection during pancreatico-
duodenectomy for cancer: a meta-analysis,” European Journal
of Surgical Oncology, vol. 40, no. 4, pp. 371–378, 2014.
[19] R. L. Smoot, J. D. Christein, and M. B. Farnell, “Durability of
portal venous reconstruction following resection during pan-
creaticoduodenectomy,” Journal of Gastrointestinal Surgery, vol.
10, no. 10, pp. 1371–1375, 2006.
[20] H. Riediger, F. Makowiec, E. Fischer, U. Adam, and U. T.
Hopt, “Postoperative morbidity and long-term survival after
pancreaticoduodenectomy with superior mesenterico-portal
vein resection,” Journal of Gastrointestinal Surgery, vol. 10, no.
8, pp. 1106–1115, 2006.
[21] K. Shimada, Y. Sakamoto, T. Sano, and T. Kosuge, “The role of
paraaortic lymph node involvement on early recurrence and
survival after macroscopic curative resection with extended
lymphadenectomy for pancreatic carcinoma,” Journal of the
American College of Surgeons, vol. 203, no. 3, pp. 345–352, 2006.
[22] P. Toomey, J. Hernandez, C. Morton et al., “Resection of por-
tovenous structures to obtain microscopically negative margins
during pancreaticoduodenectomy for pancreatic adenocarci-
noma is worthwhile,” The American Surgeon, vol. 75, no. 9, pp.
804–810, 2009.
[23] J. R. Delpero, P. Bachellier, N. Regenet et al., “Pancreatico-
duodenectomy for pancreatic ductal adenocarcinoma: a French
multicentre prospective evaluation of resection margins in 150
evaluable specimens,” HPB, vol. 16, no. 1, pp. 20–33, 2014.
[24] J. L. Gnerlich, S. R. Luka, A. D. Deshpande et al., “Microscopic
margins and patterns of treatment failure in resected pancreatic
adenocarcinoma,” Archives of Surgery, vol. 147, no. 8, pp. 753–
760, 2012.
[25] J. Wang, J. S. Estrella, L. Peng et al., “Histologic tumor involve-
ment of superior mesenteric vein/portal vein predicts poor
prognosis in patients with stage II pancreatic adenocarcinoma
treated with neoadjuvant chemoradiation,” Cancer, vol. 118, no.
15, pp. 3801–3811, 2012.
[26] S. Fukuda, E. Oussoultzoglou, P. Bachellier et al., “Significance
of the depth of portal vein wall invasion after curative resection
for pancreatic adenocarcinoma,” Archives of Surgery, vol. 142,
no. 2, pp. 172–179, 2007.
[27] G. Marangoni, A. O’Sullivan, W. Faraj, N. Heaton, and M.
Rela, “Pancreatectomy with synchronous vascular resection—
an argument in favour,”The Surgeon, vol. 10, no. 2, pp. 102–106,
2012.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
